Question
Does the combination of baricitinib and remdesivir improve outcomes in patients hospitalized with COVID-19?
Conclusion
For hospitalized patients with COVID-19 and evidence of lower respiratory tract infection, the combination of baracitinib plus remdesivir results in faster time to recovery, especially in patients who require noninvasive mechanical ventilation or high-flow oxygen. No survival benefit is seen with this combination.
Recent Posts
- Question of the Week
- Is In-person and remote physical therapy are equally effective for Chronic Knee Pain?
- The risk of breast cancer overdiagnosis is high for older women
- Severe hypocalcemia with denosumab therapy in dialysis-treated patients
- Sarilumab increases remission, decreases steroid dose in polymyalgia rheumatica taper, but at a high cost (SAPHYR)
Leave A Comment